Xilia-M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. The synergistic action of these two agents addresses multiple pathophysiological defects in type 2 diabetes, making Xilia-M 2 Tablet PR effective in achieving and maintaining target blood glucose levels. This formulation is typically prescribed when diet, exercise, and monotherapy with either agent alone do not provide adequate glycemic control. It is essential to monitor blood glucose regularly and adjust dosage based on therapeutic response and tolerability. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as the risk of hypoglycemia, particularly due to Glimepiride. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Patient counseling should emphasize adherence to lifestyle modifications and awareness of hypoglycemia symptoms. Regular monitoring of renal function and periodic assessment of glycemic parameters are recommended during therapy.